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ABSTRACT
Background. International consensus criteria (ICC) have
redefined borderline resectability for pancreatic ductal
adenocarcinoma (PDAC) according to three dimensions:
anatomical (BR-A), biological (BR-B), and conditional
(BR-C). The present definition acknowledges that
resectability is not just about the anatomic relationship
between the tumour and vessels but that biological and
conditional dimensions also are important.
Methods. Patients’ tumours were retrospectively defined
borderline resectable according to ICC. The study cohort
was grouped into either BR-A or BR-B and compared with
patients considered primarily resectable (R). Differences in
postoperative complications, pathological reports, overall
(OS), and disease-free survival were assessed.
Results. A total of 345 patients underwent resection for
PDAC. By applying ICC in routine preoperative assess-
ment, 30 patients were classified as stage BR-A and 62
patients as stage BR-B. In total, 253 patients were con-
sidered R. The cohort did not contain BR-C patients. No
differences in postoperative complications were detected.
Median OS was significantly shorter in BR-A (15 months)
and BR-B (12 months) compared with R (20 months)
patients (BR-A vs. R: p = 0.09 and BR-B vs. R:
p\ 0.001). CA19-9, as the determining factor of BR-B
patients, turned out to be an independent prognostic risk
factor for OS.
Conclusions. Preoperative staging defining surgical
resectability in PDAC according to ICC is crucial for
patient survival. Patients with PDAC BR-B should be
considered for multimodal neoadjuvant therapy even if
considered anatomically resectable.
Ductal adenocarcinoma of the pancreas (PDAC)
remains an aggressive gastrointestinal malignancy with a
poor prognosis.1 Surgical resection, in combination with
systemic chemotherapy, offers the only option for long-
term survival or even cure for patients with pancreatic
cancer. However, modern multimodal treatment approa-
ches still result in 5-year survival rates of 20–30%.2 Only
10% of patients diagnosed with PDAC are candidates for
upfront resection. Approximately one third of patients
present with borderline resectable tumours or locally
advanced disease.3 Local recurrence rates of 77% attest to
the aggressive tumour biology of PDAC. More than 50%
recur at single distant sites within the first year after
resection suggesting the presence of systemic
micrometastases at the time of resection.4,5
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To improve patient selection for surgery in order to
achieve optimal R0 resection rates, different guidelines
have been developed to define tumour resectability. In
2006, the National Comprehensive Cancer Network
(NCCN) introduced criteria that classify PDAC as
resectable (R), borderline resectable (BR), or unre-
sectable (UR)—the latter includes locally advanced disease
(LA) or metastatic disease. With special attention to BR-
PDAC, several versions have been adopted over the years.
They all share the main definition of BR adhering to the
concept of technical resectability with high risk of positive
surgical margins and consequently local progression.6–8
Accumulating evidence indicates that patients with BR-
PDAC benefit from neoadjuvant multimodal therapy,
including chemotherapy and/or radiation therapy as treat-
ment failure of surgery-first approaches in these patients
has been shown to be common in the BR-PDAC patient
cohort.9,10 Consequently, these concepts have been incor-
porated into the NCCN and further into the European
Society for Medical Oncology (ESMO) guidelines.11–13
Resectability of PDAC was traditionally determined by
the surgeon during the trial dissection. Improvements in
radiologic imaging have allowed a more accurate preop-
erative assessment of resectability.14 However, both
surgical and radiologic criteria of resectability are still
based on anatomic criteria alone. Biological and condi-
tional criteria were first described as important players of
extended resectability criteria for BR-PDAC in 2008.
However, they were not included in treatment guidelines
for BR-PDAC patients. In 2014, the International Study
Group of Pancreatic Surgery expanded the definition of
BR-PDAC by the inclusion of carbohydrate-antigen 19-9
(CA19-9) serum levels as a preoperative biological marker,
but not as a criterion for resectability.15 Finally, in 2017
international consensus was achieved for the definition of
BR-PDAC. According to these criteria, borderline-re-
sectability is defined by each of the following three
dimensions: anatomical (A), biological (B), and condi-
tional (C). Biological evaluation is performed through
measuring CA19-9 serum levels or prediction of regional
lymph node metastasis by cross-sectional imaging. The
patient’s condition is evaluated using the eastern coopera-
tive oncology group (ECOG) performance status.16
Consequently, patients are considered BR by one dimen-
sion or a combination of two or three criteria.16
Meanwhile, ICC was validated in two Asian retrospective
cohort studies. They proved to be useful and practicable in
the determination of borderline resectability in BR-
PDAC.17,18 To date, neither European nor American
guidelines have incorporated these criteria.
The purpose of this study was to evaluate retrospectively
the impact of the novel consensus criteria defining BR-
PDAC compared with current NCCN guidelines on patient
survival after upfront pancreaticoduodenectomy (PD).
MATERIALS AND METHODS
Patient Population
All patients that received upfront pancreaticoduo-
denectomy (PD) for PDAC of the pancreatic head at the
University Hospital Wuerzburg, Germany (UKW), and the
Erasmus Medical Centre Rotterdam, Netherlands, between
2003 and 2017 were identified from Institutional Database
of each hospital. During the study period, selection criteria
for upfront surgery where the same in both centres and
were based on the NCCN criteria. Patients with distant
metastasis, neoadjuvant treatment and/or arterial resection
were excluded from the study. Resected specimens were
histologically confirmed as invasive ductal
adenocarcinoma.
Patients were retrospectively assigned to four groups
(BR-A, BR-B, BR-C, or R) according to ICC on the clas-
sification of BR-PDAC.16 This was done stepwise and
prioritized according to anatomical criteria, i.e., patients
with involvement of venous or arterial vessels were
assigned to group BR-A, regardless of their CA19-9 levels.
No combinations of different ICC dimensions were cal-
culated (e.g., BR-AB). In detail, patients with a tumour
contact of less than 180 to the superior mesenteric artery
(SMA) or common hepatic artery (CHA) and/or a tumour
contact of 180 or greater to the superior mesenteric vein
(SMV) or portal vein (PV), bilateral venous narrowing,
venous occlusion, or tumour growth exceeding the inferior
border of the duodenum on the line of SMV in preoperative
cross-sectional imaging were exclusively assigned to the
BR-A group. Patients with preoperative CA19-9 serum
levels that exceeded 500 U/ml and who had not been
assigned to the BR-A group were allocated to the BR-B
group. Preoperative positron emission and computed
tomography (PET-CT) or endoscopic ultrasound to rule out
potential regional lymph node metastasis had not been
performed on a regular basis and were therefore not
accounted for in the definition of BR-B patients. No
patients with an Eastern Cooperative Oncology Group
(ECOG) status of C 2 underwent PD for PDAC at both
hospitals. Consequently, no BR-C group was to be formed.
All other patients’ tumours were staged primarily
resectable (maximum vein abutment\ 180) and assigned
to group R. The primary endpoint of this study was the
difference in overall-(OS) and disease-free survival (DFS)
between groups. Secondary endpoints were type of surgery,
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the incidence of postoperative complications according to
the Clavien-Dindo-Score,19 length of hospital stay, and
30-day mortality. Additionally, the rate of preoperative bile
drainage and differences in pathological reports were
assessed and the numbers of patients who had undergone
adjuvant chemotherapy were recorded.
Data Source
The central prospective databases of both centres pro-
vide data on patient demographics, histological diagnoses
based on International Classification of Diseases coding
standards, physician data, inpatient admission and outpa-
tient registration data, operative procedures, laboratory
values, and computerized medication records. Updated
follow-up information is ensured by continuous cross
platform integration with the Wuerzburg Comprehensive
Cancer Registry and the Netherlands Cancer Registry for
the identification of deceased patients. The records of all
patients identified were reviewed retrospectively regarding
adjuvant chemotherapy, sites of metastatic disease at pre-
sentation, disease status at last follow-up, or any missing
data. Patients’ demographic details and clinical variables
recorded at the time of primary diagnosis as well as during
the initial operation (tumour site and the presence of any
metastases) were compiled. Histological details of resected
specimens were categorized according to the TNM staging
system of pancreatic cancer (8th edition) of the American
Joint Committee on Cancer/Union Internationale Contre le
Cancer (AJCC/UICC-TNM) as follows: tumour (T) stage,
nodal (N) stage, tumour differentiation (G), and evidence
of microscopic venous (V), lymphatic vessel (L), or per-
ineural invasion (Pn)). The reporting pathology system on
the resection status has changed over the study period.
Therefore, R0 resection status was defined as no
detectable tumour cells at the transection or circumferential
margin (CRM) according to the currently valid definition
of ‘‘CRM narrow.’’
Treatment
All patients underwent physical examination and were
staged by multidetector computed tomography of the tho-
rax and abdomen to rule out distant metastases. Patients
with total bilirubin levels[mg/dl underwent biliary drai-
nage prior to surgery. In case of limited obstructive
jaundice (\ 15 mg/dl) and missing signs of acute cholan-
gitis primary resection was performed in patients with
suspected PDAC. For this study, we used only CA19-9
levels after stent placement and as close as possible before
the day of surgery. All patients underwent pancreatico-
duodenectomy (PD) that was either pylorus-resecting
according to Kausch and Whipple or pylorus-preserving
according to Traverso and Longmire as well as systematic
lymphadenectomy. In some patients, complete pancreate-
ctomy was necessary to achieve tumour-free resection
margins. All patients were discussed in a multidisciplinary
team conference at the time of diagnosis and after surgery.
Adjuvant treatment consisted of Gemcitabine 1000 mg/m2,
6 cycles of 3 weeks followed by 1-week rest.20
Follow-Up
The German national (AWMF) and European (ESMO)
guidelines do not recommend a regular follow-up after
initial therapy with curative intent.11,12 Nevertheless, most
patients treated at both centres underwent reevaluation of
postoperative tumour burden by cross section imaging
before or after adjuvant chemotherapy. Postoperative fol-
low-up consisted of outpatient assessments on demand or
the gathering of complete information from patients’ pri-
mary care physicians. CT scans were performed on demand
whenever recurrence was suspected based on the patients’
physical condition, complaints, or elevated tumour mark-
ers. OS was defined as the time period from the date of
surgery to the date of death by any cause. DFS was defined
as a time period from the date of surgery to the date of
tumour recurrence or death. Patients who died postopera-
tively were excluded from the survival analysis.
Statistical Analysis
Data were analysed with IBM SPSS Statistics Version
25. Clinical and histological parameters were compared
with the analysis of variance (ANOVA), Chi square, and
Fisher exact test, as appropriate. Survival curves were
drawn according to Kaplan–Meier methods. Log-rank test
was used for comparison of survival analysis. Holm-Bon-
ferroni correction was applied to accommodate multiple
testing in subgroup analysis.21,22 Preoperative and patho-
logical variables with a p value\ 0.1 in the univariate
analysis were included into a Cox proportional hazards
model using a backward stepwise selection to determine
the independent risk factors associated with OS and DFS.
A p value\ 0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Between January 2003 and December 2017, 345 patients
were diagnosed with adenocarcinoma of the pancreatic
head and met the inclusion criteria. The cohort consisted of
208 male and 137 female patients, with a median age of 69
(range 33–90) years and a median preoperative body mass
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index (BMI) of 25.0 kg/m2 (range 16–41). The most
common ASA scores were 2 and 3 (89.6%). Most patients
presented with obstructive jaundice (72.3%). Conse-
quently, serum bilirubin-levels were raised to 1.8 mg/dl in
the median ranging from 0.2 to 40.4 mg/dl. A total of 197
patients (57.1%) underwent preoperative bile drainage.
Patients received biliary stenting either during the initial
diagnostic workup in a community hospital or because of
pending cholangiosepsis. The median serum CA19-9 level
was 132 U/l (range 0.6-23898). According to the ICC, 92
patients were staged BR: 30 patients (8.7%) due to
anatomical criteria (BR-A) and 62 patients (18.0%) due to
CA19-9 serum levels exceeding 500 U/l (BR-B). Patient
characteristics are listed in Table 1.
Surgery and Postoperative Complication Rate
In both departments, pylorus-preserving PD is the
standard procedure for pancreatic head resections. Tech-
nical variations in terms of additional distal gastrectomy or
completing-pancreatectomy are based on the surgeon’s
intraoperative decision and/or frozen-section results to
achieve tumour-free resection margins. Consequently, 203
(58.8%) pylorus-preserving PD, 123 (35.6%) pylorus-re-
secting PD and 19 (5.5%) total pancreatectomy procedures
were performed. In the BR-A group, complete pancreate-
ctomy as a consequence of repeated positive resection
margins on frozen sections was performed significantly
more often (16.6%) compared with the BR-B (8.0%) and
R (3.5%, p\ 0.010) groups. Overall postoperative mor-
bidity was 53.6%. We did not detect intergroup variations
with regard to total complications. However, patients in the
BR-A group developed significantly less major postoper-
ative complications (Clavien-Dindo C Grade IIIa).
There was no difference in length of hospital stay
between groups. The 30-day mortality rate was 0% in the
BR-A group (0%), 8.1% in the BR-B (8.1%), and 2.8% in
the R group (p = 0.069). Table 2 summarizes the infor-
mation on postoperative morbidity and mortality rates
between groups.
Pathological Reports and Adjuvant Chemotherapy
According to the tumour-node-metastasis system (8th
edition of TNM23) introduced by the AJCC/UICC-TNM,
most patients were classified into T2 (65.8%) and N1
(58.5%) categories. No differences in UICC stages were
observed between groups. Median tumour diameter was
significantly larger in the BR-A group (p = 0.003), but
tumour stages (T) did not differ significantly between
groups (p = 0.296). BR-A (63.3%) and BR-B (88.7%)
patients were significantly more often nodal-positive than
patients in the R group (57.1%) (p = 0.010). The highest
N2 rates were detected among BR-B patients (29.0%).
There were marked intergroup differences in positive
resections margins and tumour grading (G). Pathological
examination of pancreatic head specimens revealed that
positive resection margins (R1) occurred significantly more
often in patients staged BR-A (46.7%) and BR-B (40.3%)
than in those tumours staged primarily resectable (19.8%,
p = 0.001). Patients classified into BR-A or BR-B showed
significantly worse tumour grading (G3/G4) than those
assigned to the R group (p = 0.003). No difference with
regard to perineural or lymphatic vessel infiltration rates
was detected. Approximately 50% of patients received
adjuvant chemotherapy in either group. Detailed pathologic
information is outlined in Table 2.
TABLE 1 Patient characteristics
Patient population All BR-A BR-B R p value
No. of patients (n, %) 345 30 (8.7) 62 (18.0) 253 (73.3)
Age (year, median (min–max)) 69 (33–90) 66 (35–88) 70 (49–82) 69 (33–90) 0.181
Gender male (n, %) 208 (60.3) 15 (50.0) 39 (62.9) 154 (60.9) 0.463
BMI (kg/m2, median (min–max)) 25.0 (16.1–41.1) 24.0 (19.6–30.9) 25.1 (16.5–39.3) 25.1 (16.1–41.1) 0.471
ASA score (n, %)
1 18 (5.2) 3 (10.0) 2 (3.2) 13 (5.1)
2 190 (55.1) 21 (70.0) 31 (50.0) 143 (56.5)
3 119 (34.5) 6 (20.0) 27 (43.5) 86 (40.0)
4 3 (0.9) 0 (0) 2 (3.2) 1 (0.4) 0.107
Bilirubin (mg/dl, median (min–max)) 1.8 (0.2–40.4) 1.8 (0.5–18.2) 7.1 (0.4–29.2) 1.4 (0.2–40.4) 0.001
Preoperative biliary stent (n, %) 197 (57.1) 17 (56.7) 27 (43.5) 153 (60.5) 0.054
CA19-9 (U/l, median (min–max)) 132 (1–23898) 145 (1–7408) 997 (502–23898) 76 (0.6–500.0) \ 0.001
Median overall survival (mo, median (95% CI)) 18 (15.9–20.1) 15 (8.0–22.0) 12 (8.9–15.0) 20 (17.6–22.4) \ 0.001
Median disease-free survival (mo, median (95% CI)) 11 (9.2–12.8) 5 (1.6–8.4) 8 (6.4–9.6) 13 (11.4–14.6) \ 0.001
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Oncological Outcome and Risk Factors of Overall
Survival
Lost to follow-up was 10.0% in the BR-A group, 12.3%
in the BR-B group, and 19.9% of patients in the R group.
With regard to the entire study population, the median
disease-free survival (DFS) was 10 months (Fig. 1a) and
overall survival (OS) was 18 months (Fig. 1c). The median
DFS was significantly shorter in patients staged BR-A
(5 months) and BR-B (7 months) compared with patients
TABLE 2 Perioperative and pathological parameters according to patient subgroups BR-A, BR-B, and R
BR-A
n = 30
BR-B
n = 62
R
n = 253
p value
Surgery and postoperative complications
Traverso–Longmire (n, %) 11 (36.7) 37 (59.7) 155 (61.3)
Kausch–Whipple (n, %) 14 (46.7) 20 (32.3) 89 (35.2)
Pancreatectomy (n, %) 5 (16.6) 5 (8.0) 9 (3.5) 0.010
Total operation time (min, median (min–max)) 379 (237–634) 363 (206–589) 351 (195–756) 0.099
Clavien-Dindo C IIIa (n, %) 2 (6.7) 17 (27.4) 87 (34.4) 0.007
Reoperation rate (n, %) 2 (6.7) 7 (11.3) 37 (14.6) 0.418
Length of hospital stay (days, median (min–max)) 12.5 (3–37) 19 (7–61) 18 (5–173) 0.017
30-day mortality 0 (0.0) 5 (8.1) 7 (2.8) 0.069
Pathological reports
Tumour status (n, %)
T1 3 (10.0) 9 (14.5) 47 (18.6)
T2 18 (60.0) 43 (69.4) 166 (65.6)
T3 9 (30.0) 10 (16.1) 40 (15.8) 0.296
Largest tumor diameter (cm, median (min–max)) 3.6 (1.5–7.5) 3.0 (1.0–6.0) 2.8 (0.2–8.0) 0.003
Lymph node status (n, %)
N0 11 (36.7) 7 (11.3) 55 (21.7)
N1 11 (36.7) 37 (59.7) 154 (60.9)
N2 8 (26.6) 18 (29.0) 43 (17.0) 0.010
Lymphovascular tumour invasion (n, %)
L0 5 (16.7) 20 (32.3) 73 (28.9)
L1 25 (83.3) 42 (67.7) 180 (71.2) 0.681
Perineural tumour invasion (n, %)
Pn0 1 (3.3) 13 (21.0) 44 (17.4)
Pn1 29 (96.7) 49 (79.0) 209 (82.6) 0.140
Resection status (n, %)
R0 16 (53.3) 37 (54.7) 203 (80.2)
R1 14 (46.7) 25 (40.3) 50 (19.8) 0.001
Tumour grading (n, %)
G1 3 (10.0) 2 (3.2) 19 (7.5)
G2 14 (46.7) 29 (46.8) 165 (65.2)
G3 13 (43.3) 28 (45.2) 68 (26.8)
G4 0 (0.0) 3 (4.8) 1 (0.4) 0.003
UICC stage (n, %)
1a 3 (10.0) 3 (4.8) 19 (7.5)
1b 5 (26.7) 4 (6.5) 31 (12.3)
2a 3 (10.0) 0 (0.0) 8 (3.2)
2b 11 (36.7) 37 (59.7) 153 (60.5)
3 8 (26.6) 18 (29.0) 42 (16.6) 0.074
Adjuvant chemotherapy (n, %) 15 (50.0) 27 (43.5) 125 (49.4) 0.634
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staged R (12 months, BR-A vs. R: p = 0.003, BR-B vs. R:
p\ 0.001; Fig. 1b). The median OS was significantly
shorter in patients staged BR-B (12 months) and showed a
clear trend towards a shorter OS in the BR-A group
(15 months) compared with patients staged R (20 months,
BR-B vs. R: p\ 0.001, BR-A vs. R = 0.09, Fig. 1d).
First, the two dimensions of BR and several histological
factors were analysed for their prognostic impact on OS in
univariate analysis (Fig. 2; Table 3a). BR-B (p\ 0.001), a
nodal-positive PDAC (p\ 0.001), a positive lymphovas-
cular (p = 0.001) or perineural infiltration (p = 0.028),
positive resections margins (p = 0.001), or no adjuvant
chemotherapy (p = 0.002) were associated with a signifi-
cantly worse overall survival of PDAC patients.
Interestingly, subgroup analysis of all patients with pre-
operative CA19-9 serum values above 500 U/ml showed
that the resections margins (R0 vs. R1) lost impact on
overall survival in this patient cohort (Fig. 3). In multi-
variable analysis, BR-B (HR 1.53, p\ 0.001) together
with lymph node metastasis (HR 1.92, p\ 0.001), lym-
phovascular invasion (HR 1.68, p = 0.001), positive
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resection margins (HR 1.43, p = 0.012), and failure to
adjuvant chemotherapy (HR 1.73, p\ 0.001) turned out to
be independent prognostic risk factors of OS (Table 3a).
Second, BR-A (p = 0.005), BR-B (p = 0.001), N1/2
(p\ 0.001), L1 (p\ 0.001), Pn1 (p = 0.064), R1
(p = 0.023), and no adjuvant chemotherapy (p = 0.012)
were identified as prognostic risk factors for DFS in uni-
variate analysis (Table 3b). A multivariable analysis
revealed lymph node metastasis (HR 1.85, p\ 0.001),
lymphovascular invasion (HR 1.58, p\ 0.001), no adju-
vant chemotherapy (HR 1.64, p\ 0.001), BR-A (HR 2.22,
p\ 0.001), and BR-B (HR 1.4, p = 0.025) as independent
prognostic risk factors for DFS (Table 3b).
DISCUSSION
There is accumulating evidence that neoadjuvant treat-
ment protocols result in a survival benefit for patients with
BR-PDAC.9,24 However, most studies were nonrandom-
ized, BR-definitions heterogenous and only attributed to
anatomical borderline-resectability. So far, three RCTs
have been published that have analysed the prognostic
impact of different neoadjuvant treatment protocols in
anatomically borderline-resectable and primarily
resectable PDAC patients.25–27 Results of the Korean and
Japanese trials showed a survival benefit especially for BR
PDAC patients,25,26 whereas the European trial did not
show a significantly improved overall survival. However,
survival analysis of patients who underwent tumour
resection and started adjuvant chemotherapy showed
improved survival with preoperative chemoradiotherapy.27
In this study, we retrospectively assigned patients from two
European centres with BR PDAC to different preoperative
groups according to the new International consensus cri-
teria (ICC). Although the association of CA 19-9 elevation
and outcome has been demonstrated in numerous series,28
we were able to show for the first time in a European
patient cohort that biology based on preoperative CA 19-9
levels is at least as important as anatomy in defining
resectability of patients with adenocarcinoma of the pan-
creatic head. This study demonstrated that preoperative
staging of borderline resectability according to the new
international consensus criteria resulted in significant sur-
vival differences for subsets of patients who had undergone
upfront resection surgery for PDAC. First, tumour
involvement along the portal and/or mesenteric vein dra-
matically reduced DFS and OS, which was comparable to
studies that included patients with BR-PDAC and venous
or arterial invasion.9,18 Second, we identified a subset of
patients that was classified BR from having elevated CA
19-9 serum levels with an equal or even stronger reduction
in DFS and OS as patients with anatomically borderline
resectable disease. However, according to current guideli-
nes, such as NCCN or ESMO, these patients would still be
scheduled for upfront resection. In contrast, our results
clearly indicate that disease-free and overall survival of
BR-B patients is at least as compromised as of patients who
were classified BR due to anatomic reasons (BR-A).
TABLE 3 Univariate and multivariable analysis
Clinical factor Patients
n = 333
Univariate
p
Multivariable
HR 95% CI p
(a) Pre- and postoperative parameters associated with OS
BR-A 30 0.121
BR-B 57 \ 0.001 1.53 1.11–2.11 0.010
T-Status[ 2 56 0.148
N-Status C 1 262 \ 0.001 1.94 1.42–2.67 \ 0.001
L-Status = 1 156 0.001 1.38 1.08–1.78 0.012
Pn-Status = 1 235 0.028 1.16 0.87–1.53 0.313
R-Status = 1 79 0.001 1.43 1.08–1.89 0.012
no adj. CTx 142 0.002 1.73 1.35–2.21 \ 0.001
(b) Pre- and postoperative parameters associated with DFS
BR-A 30 0.005 2.22 1.47–3.34 \0.001
BR-B 57 0.001 1.42 1.05–1.94 0.025
T-Status[ 2 56 0.117
N-Status C 1 262 \ 0.001 1.85 1.36–2.52 \ 0.001
L-Status = 1 156 \ 0.001 1.58 1.24–2.02 \ 0.001
Pn-Status = 1 161 0.064 1.05 0.80–1.39 0.693
R-Status = 1 49 0.023 1.11 0.84–1.47 0.464
no adj. CTx 83 0.012 1.64 1.28–2.09 \ 0.001
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FIG. 3 Overall survival by resection status (R0 vs. R1) in patients
with preoperative CA19-9 serum-level above 500 U/ml. Survival
curves are drawn according to Kaplan–Meier with patients at risk
below each graph
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According to our results, ICC turned out to be more precise
in defining resectability in PDAC patients according to
their survival analysis. Therefore, ICC should be imple-
mented in diagnostic and treatment algorithms for patients
with pancreatic head cancer.
In this context, some aspects of the ICC need to be
addressed. Regarding anatomical criteria to define
resectability of PDAC, NCCN, and ESMO guidelines are
both based on tumour involvement of vessels along the
porto-mesenteric axis.12,13 ICC extend these criteria by a
further anatomic landmark in preoperative imaging, i.e.,
the inferior border of the duodenum on the line of SMV.16
Tumour growth beyond this landmark would account for
locally advanced disease and no curative resection option.
It must be stated that this consensus is rather weak, because
it was based on only two patients who did not undergo
resection for that reason.16 In our study, none of the
patients staged BR-A presented with tumour growth
exceeding the inferior border of the duodenum. As
expected, BR-A patients showed a significantly higher
number of nonradical resections (R1). Interestingly, this
also was true for BR-B patients who had been preopera-
tively staged anatomically resectable. Probably the
preoperative imaging might have underestimated the extent
of the tumour size in patients with high preoperative CA19-
9 levels. However, our data confirm previous reports that
preoperatively elevated CA19-9 levels correlate with the
resection status of the pancreatic head specimen with R1
resections rate of 55% for patients with CA19-9 above 500
U/ml.29 Consequently, our results support current NCCN
guidelines recommending neoadjuvant therapy at least for
BR-A patients, as this therapeutic algorithm significantly
reduces R1 resection rates in BR-A patients.25,30 Because
the definition of R0 has changed over time and the concept
of a circumferential resection margin (CRM) has been
introduced during the study period, we defined R0 resec-
tion status as no detectable tumour cells at the transection
or circumferential margin (CRM) according to the cur-
rently valid definition of ‘‘CRM narrow.’’ This might have
resulted in an overall underrepresentation of positive
resection margins and a possible bias in survival data, as
the redefinition of a negative resection margin by the
German guideline in 2013 led to a significant reduction of
so called curative resections in large patient cohorts.31 The
higher rate of Clavien-Dindo C IIIa complications in the
R and BR-B group compared with BR-A might be due to
the consistency of the pancreatic remnant and duct size,
which is usually soft in patients with anatomically
resectable tumor without pancreatic duct obstruction. Some
studies reported about the prognostic impact of postoper-
ative complications following pancreatic head resections
on overall survival with inconsistent results.32,33 Nonuni-
form grading systems for postoperative complications and
study populations, including patients after neoadjuvant
treatment who per se show an impaired survival compared
with primarily resectable PDAC patients, might have
influenced different outcome results. Treatment delays or
even omission of adjuvant chemotherapies have been dis-
cussed to influence overall survival.34 Although
complication rates were different between groups in this
study, approximately 50% of patients received adjuvant
chemotherapy in all groups.
The main novelty in defining BR-PDAC according to
ICC constitutes the incorporation of preoperative CA19-9
serum levels as a function of tumour biology. By applying
the proposed cutoff value of 500 U/ml, we identified 62
patients in our cohort. Interestingly, these patients pre-
sented with a larger extend of lymph node metastasis, a
higher R1 resection rate, worse tumour grading, and
shortened DFS and OS compared with patients staged
R according to ICC. These findings indeed indicate to a
more aggressive tumour biology of BR-B PDAC. In a
retrospective analysis of Japanese patients who had also
received upfront resection surgery for PDAC, Kato et al.
proposed a CA19-9 cutoff value of 1000 U/l for the defi-
nition of borderline resectability according to the
multivariate analysis.18 In our study, CA19-9 values were
set as suggested by ICC and proved to be an independent
prognostic marker for DFS and OS. Most interestingly, the
impact of the resection status on overall survival gets lost
in this patient cohort. Patients with serum CA19-9 levels of
more than 500 U/ml do not show differences in overall
survival according to the resection status (R0 vs. R1). Of
note, the ICC consensus statement is based on a large
German cohort analysis, describing a continuous decline in
resection rate and median survival time with a rise in
preoperative CA19-9 serum levels.29 It is known that the
positive predictive value of CA19-9 in order to determine
malignant disease is 72.3%35 and that 7-10% of the Cau-
casian population are non-secretors due to their ABO-
type.36 This might result in an underrepresentation of
biologically aggressive tumours. But CA19-9 has been
used in risk profiling of PDAC patients for years and—to
our knowledge—there is no alternative serum marker in
PDAC patients available so far that resembles tumour
biology more reliably than CA 19-9. Another advantage of
CA 19-9 is that it allows a first approximation of the
individual tumour biology without the need for a tumour
biopsy, because it serves as a prognostic marker in different
malignant entities of the pancreatic head (e.g., distal
cholangiocarcinoma37). We do respect that a large variety
of genetic and molecular variations have been identified in
pancreatic cancer (i.e., K-ras, p16, p53, BRCA2, smad4
genes) in the past.38 However, translation of this scientific
knowledge into clinical treatment regimen is still largely
unrealized. At present, serum CA19-9 may therefore
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qualify best. There also have been conflicting reports on
the interaction of CA19-9 and hyperbilirubinemia as
increased pressure on the common bile duct has been
postulated to be linked with increased CA19-9. Relief of
jaundice was described to be associated with a decrease of
CA19-9 in a substantial amount of patient with benign and
malignant diseases.39,40 Consequently, subsequent studies
have ruled out patients with increased bilirubin levels or
have calculated adjusted CA19-9 levels.41 A more recent
study on a large patient PDAC patient population con-
firmed this correlation, but more importantly found that the
correlation coefficient was very low.29 The authors con-
cluded that adjusted CA19-9 levels are not mandatory.
Appropriate cutoff values might vary within different
patient cohorts and therefore need to be further analysed in
prospective studies. Furthermore, because all patients with
bilirubin levels[ 15 mg/dl underwent biliary drainage
before surgery in this study, we used CA19-9 levels
determined just before surgery when bilirubin levels were
normalised in most patients.
Apart from CA19-9 levels, ICC considers preoperative
lymph node evaluation in terms of metastases for the def-
inition of biological borderline resectability in PDAC
patients (BR-B). In our study, the preoperative evaluation
for the likelihood of lymph node metastases was not
assessed by PET-CT and lymph node biopsy was not
routinely performed. Lymph node metastasis is a well-
known independent prognostic factor42,43—as underlined
by our results. However, reliable prediction of lymph node
metastasis in PDAC remains challenging.44 The highest
negative predictive value of 93.3% for preoperative
determination of lymph node metastasis in pancreatobiliary
tumours was reported from MRI studies.45 These promis-
ing results should encourage further improvements in
preoperative imaging techniques with the chance to clas-
sify patients with greater accuracy into BR-B according to
lymph node status. In our patient cohort, N2-category
occurred twice as often in patients staged BR-B compared
with other groups. Possibly, CA19-9 serum levels might
additionally help to assess the extent of lymph node
metastases preoperatively.46
The following issues need to be addressed. First,
because this is a retrospective study and lost to patient
follow-up was considerable, patient selection bias cannot
be ruled out, especially because the approach to patients
with vascular involvement changed over time to neoadju-
vant therapy. Because upfront resections in patients with
borderline disease has only been recommended since the
2016 version of the NCCN guidelines, most patients with
BR-A disease underwent an explorative laparotomy.
However, the results of this study confirm those reported
by Kato et al.,18 who showed an impaired survival of
patients staged BR-B compared with patients staged R ac-
cording to ICC by using a similar study design.
Nevertheless, prospective validation of the current results
along with calculation of appropriate cutoff values for
CA19-9 serum levels is needed together with describing
the recurrence pattern in both groups to define the poor
prognosis of the BR-B group. Second, due to low patient
numbers (n = 6) we did not analyse BR-AB patients as an
independent group but included them in the BR-A group.
In these patients, the impact of tumour biology in terms of
elevated CA19-9 levels might have been trumped. Third,
due to the overall low number of patients who received
adjuvant treatment as a reflection of changes in national
recommendations for the treatment of PDAC over the
study period, we observed a rather short median DFS and
OS. Consequently, missing adjuvant treatment was an
independent prognostic risk factor for DFS and OS.
However, distribution of patients who received adjuvant
treatment was equal between groups and thus does not
explain the differences in OS. Fourth, the preoperative
staging of PDAC improved over time thereby increasingly
determining treatment proposals in multidisciplinary con-
ferences, ultimately evolving the concept of multimodal
neoadjuvant therapy for borderline resectable PDAC with
considerable oncological benefit.25 Given the fact that
evaluation of patients with PDAC varies between different
interdisciplinary conferences,47 resection criteria for PDAC
should be defined more precisely. Because the outcome of
the so-called biological borderline group (preoperative CA
19-9 serum levels[ 500 U/ml) is so poor, new neoadju-
vant regimens, including FOLFIRINOX, should be
evaluated in randomized clinicals trials in this cohort of
patients.
CONCLUSIONS
Preoperative staging in terms of defining surgical
resectability according to ICC is crucial for survival of
patients diagnosed with PDAC. Apart from anatomical
factors, prognosis of PDAC patients is substantially
dependent on preoperative CA19-9 serum levels according
to our data. Therefore, not only PDAC patients staged BR-
A should be considered for neoadjuvant multimodal ther-
apy but also BR-B patients, even if considered
anatomically resectable. Future studies need to determine
appropriate cutoff values for CA19-9.
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